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ABSTRACT 
Background Chronic idiopathic constipation is a common symptom-based 
gastrointestinal disorder responsible for a substantial economic health service 
burden. Current guidelines recommend the use of fibre as first-line treatment. 
Aim To investigate the effect of fibre (including prebiotic) supplementation on global 
symptom response, stool output, gut microbiota composition and adverse events in 
adults with chronic idiopathic constipation. 
Methods Medline, Embase, Web of Science, Scopus, and the Cochrane central 
register of controlled trials were searched through to February 2016. Conference 
proceedings from 2003-2015 were hand searched. There were no language 
restrictions. Forest plots with 95% CIs were generated using a random effects model. 
Results The search strategy generated 1072 citations, of which 7 individual 
randomised controlled trials were eligible. Overall, 113 of 147 (77%) patients 
assigned to fibre responded to therapy, compared with 61 of 140 (44%) allocated to 
placebo (RR of success to respond 1.71, 95% CI 1.20 to 2.42, P=0.003). Fibre 
significantly increased stool frequency (SMD=0.39; 95% CI 0.03 to 0.76; P=0.03) and 
softened stool consistency (SMD=0.35; 95% CI 0.04 to 0.65; P=0.02) compared with 
placebo. Flatulence was significantly higher with fibre compared to placebo (SMD 
0.56, 0.12 to 1.00, P=0.01). Overall quality of evidence was low. 
Conclusions This meta-analysis demonstrates that fibre is moderately effective but 
also causes moderate gastrointestinal side effects. However, these findings need to 
be treated with caution due to high risk of bias. Accordingly, further large, 
methodologically rigorous trials are required, before any definitive recommendation 
regarding its risk-benefit profile can be made.  
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INTRODUCTION 
Chronic idiopathic constipation (CIC) is a heterogeneous symptom-based disorder 
with an estimated global prevalence of 14%1 characterized by infrequent defecation, 
difficult stool passage, or a combination of the two in the absence of an organic 
cause.2 Females have been shown to be two to three times more likely to have CIC 
than men.3 CIC is associated with impaired quality of life,4 increased risk of colorectal 
cancer5 and is responsible for a substantial economic health service burden.6 The 
pathophysiology of CIC is multifactorial and incompletely understood. Beyond simple 
lifestyle advice (e.g. increasing fluid intake and levels of exercise), laxatives are a 
widely used treatment7 but are associated with suboptimal outcomes due to variable 
efficacy, adverse events, cost, taste and inconvenience.8 
 
First line management as recommended in British, American, European and other 
global guidelines, as well as expert commentaries, is fibre supplementation.9-13 Fibre 
intake may accelerate whole gut transit time, by increasing luminal bulk resulting in 
increased peristalsis.14 Fibre can also influence bulking directly via water retention 
which also normalises stool form.15-16 Further, fermentation of fibre can increase stool 
bulk by increasing microbial biomass and fermentation by-products, such as short 
chain fatty acids.17 Gut transit time may also be indirectly accelerated through 
lowering of luminal pH and possibly through secondary effects on the gut 
microbiota.18 Nevertheless, up to 50% of patients do not respond or become 
dissatisfied with fibre as a treatment stratagem.19 The term fibre refers to 
carbohydrate polymers with three or more monomers that are not hydrolysed by 
endogenous enzymes in the human small intestine.20 This definition also includes 
prebiotics, which are soluble fibres that are selectively fermented and result in 
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specific changes in the composition and/or activity of the gut microbiota, and are 
postulated to confer health benefit(s) upon the host.21 
 
The efficacy of fibre in the management of CIC in adults has been documented in a 
previous systematic review.22 However, to date there has been no definitive 
quantitative summary of available evidence and outcomes (particularly on the effect 
of prebiotics on gut microbiota composition). Thus, we aimed to address this 
knowledge gap by objectively assessing the effect of fibre supplementation on 
measures of: (I) response to therapy, (II) stool output, (III) gut microbiota 
composition, and (IV) adverse events in adults with CIC. 
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METHODS 
 
A systematic review and meta-analysis was performed following the guidelines of the 
Cochrane Handbook for Systematic Reviews of Interventions,23 and reported in line 
with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines.24 
 
Search strategy and study selection 
 
A literature search for randomised controlled trials (RCTs) evaluating fibre 
supplementation used in the treatment of CIC in adults was conducted. A database 
search was performed in February 2016 using MEDLINE, EMBASE, WEB OF 
SCIENCE, SCOPUS and The Cochrane Central Register of Controlled Trials. No 
date limitations were applied and searches were not restricted by language. Studies 
on CIC were identified with the terms: constipation OR gastrointestinal transit [both 
as medical subject headings (MeSH) and free text terms]. These were combined 
using the set operator AND with studies identified with the terms: fibre OR psyllium 
(both as MeSH terms and free text terms). Results were then further combined with 
the operator AND with highly sensitive search filter for identifying RCTs. The detailed 
search strategy for MEDLINE is presented in Table S1. Reference lists of eligible 
studies, as well as reference lists of previous systematic reviews on fibre and 
constipation, were manually scanned for additional studies not identified by the 
electronic searches. An attempt to identify completed but unpublished trials was 
performed by searching the ClinicalTrials.gov and www.isrctn.com databases. Finally, 
abstracts of the following conference proceedings were hand-searched to identify 
potentially relevant studies: Digestive Diseases Week (2003–2015), British Society of 
Gastroenterology Annual Meeting (2003-2015), and United European 
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Gastroenterology Week (2009–2015). Titles and abstracts identified from the search 
strategy were evaluated by two independent investigators (SC and ED) using pre-
defined eligibility criteria. The full text of any title or abstract deemed potentially 
eligible by either investigator was retrieved and foreign language papers were 
translated when required. Subsequently, the two reviewers independently assessed 
the eligibility of each full-text article and disagreements were resolved by consensus 
with a third researcher (SMS).  
 
Eligibility criteria 
 
The eligibility criteria were developed using the Population, Intervention, Comparator, 
Outcomes, Study design (PICOS) approach.25 Population - adults (≥18 years old) 
with CIC diagnosed using clinical diagnosis, self-report or Rome criteria. Only studies 
in which patients were recruited from community or outpatient settings were included. 
Intervention - studies using supplementary fibre as defined by the Commission of 
European Communities (2008).20 Comparator - studies comparing fibre (including 
prebiotic) supplements with placebo/control. Trials were also included if they reported 
interventions with supplementary fibre in combination with other ingredients (active 
comparators) as long as the effect of fibre could be isolated. Outcomes - studies 
reporting either dichotomous or continuous data on overall response to therapy, stool 
output, gut microbiota concentrations and adverse events. Study Design - RCTs with 
parallel group design, or the first period of crossover RCTs (to reduce the risk of 
carryover effect) were considered eligible for inclusion. 
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Data extraction 
Two investigators (SC and ED) independently extracted data on patient 
characteristics, interventions, comparators, measure outcomes, and study design 
using standardised data extraction forms. Authors of included studies were contacted 
for missing data and their responses were included in the analyses. Whenever 
allowed by trial reporting, data were extracted as intention-to-treat analyses, with all 
drop-outs assumed to be treatment failures for dichotomous outcomes (i.e. no 
response to therapy). If this was not clear from the original article, an analysis on all 
patients with reported evaluable data was undertaken. 
 
Assessment of risk of bias  
The two investigators independently assessed risk of bias according to the Cochrane 
Collaboration handbook,23 with disagreements resolved by discussion. Studies were 
assessed for the methods used to generate randomisation, conceal allocation, 
blinding, incomplete outcome data, selective reporting, and other sources of bias. 
Furthermore, the overall quality of evidence (confidence in effect estimates) for each 
outcome was rated by using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach.26 Quality of evidence was rated 
from high to very low.27 
 
 
Data synthesis and statistical analysis 
 
Data were pooled using a random effects model, to give a more conservative 
estimate of the effect of fibre supplementation on CIC, allowing for heterogeneity 
between studies.28 The estimates of treatment effects were expressed as relative risk 
(RR) and 95% confidence interval (CI) for dichotomous outcomes (response to 
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therapy) and standardized mean difference (SMD) with 95% CI for continuous 
outcomes (stool frequency, stool consistency, gut microbiota concentrations, adverse 
events). SMD was used as a summary statistic for all continuous outcomes because 
the studies measured the same outcome using varied scales or because no details of 
the scale and scoring system were reported, which prevented the data being 
converted to the same unit, thus prevented calculation of the mean difference. SMD 
values of 0.2, 0.5 and 0.8 were defined as small, moderate and large effect size 
respectively.29 The number needed to treat (NNT) and 95% CIs were calculated for 
response to therapy using the formula: NNT=1/(1-RR) × assumed control group 
risk.23 Furthermore, the precision of the estimate of effect for the primary outcome 
was tested by calculating the optimal information size using α (0.05) and β (0.20) 
values, and a relative risk reduction of response to therapy of 30%.30 Heterogeneity 
between studies was assessed using the I2 statistic with a cut-off of 25%,31 and/or 
the chi-square test, with a P-value <0.10 to define significant heterogeneity. I2 
statistic values of 25%, 50% and 75% were defined as low, moderate and high 
heterogeneity respectively.32 Subgroup analyses were carried out to explore possible 
causes of heterogeneity and subgroup-treatment interactions using the chi-square 
significance test.33 An interaction p-value of <0.10 was considered as a cut-off.34 
Forest plots with 95% CIs were generated for all outcomes using Review Manager v. 
5.3 (Copenhagen, Denmark) and Stata v.12.0 (StataCorp, Stata Statistical Software, 
College Station, Texas, USA). Funnel plots were generated, where sufficient number 
of studies were identified, to assess for evidence of asymmetry and therefore 
possible publication bias or other small study effects;35 these were evaluated by both 
observing the funnel plots and using Egger’s test analysis.36 A two-tailed p-value 
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≤0.05 was adopted as the statistical criterion. The kappa statistic for inter-observer 
agreement between the two reviewers was also calculated.37 
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RESULTS 
Study selection 
The search strategy generated 1072 citations, of which 1064 studies were identified 
from the primary electronic databases and 8 studies identified through manual 
search. Of these, 377 were duplicates leaving 695 records to be screened, of which 
52 were potentially relevant and retrieved for full-text review (Figure 1). Of these, 45 
were excluded with 7 RCTs ultimately eligible.38-44 Agreement between investigators 
for trial eligibility was substantial (kappa statistic=0.80). 
 
Study characteristics  
The seven RCTs comparing fibre supplementation with placebo/control involved a 
total of 430 adults with CIC.38-44 Six studies were published in English and one in 
Spanish.42 Authors of six of the trials were contacted to obtain supplementary 
information about the methodology used.39-44 Of these, four provided responses that 
were included in the analyses.39-41, 44 Table 1 shows the definition of chronic 
idiopathic constipation used in the included studies, and Table 2 details the 
characteristics of the included studies. There was considerable variability in the type 
(e.g. psyllium, inulin) and dose (10 to 22.5g/d) of fibre studied. Treatment periods 
varied from two to eight weeks and the proportion of women in the trials ranged 
between 64% and 100%. 
 
Efficacy and safety of fibre in the treatment of CIC 
Response to therapy 
Dichotomous data on response to therapy, measured by symptomatic improvement, 
were reported by four RCTs38, 41-42, 44 including 287 patients. Overall, 113 of 147 
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(77%) patients assigned to fibre responded to therapy, compared with 61 of 140 
(44%) allocated to placebo (RR of success to respond=1.71; 95% CI 1.20 to 2.42; 
P=0.003), with borderline heterogeneity between studies (I2=24%, χ2 P=0.27). 
Overall, the NNT with fibre to result in response in one patient was 3 (95% CI 2.6 to 
3.4). Given the borderline heterogeneity, subgroup analyses were conducted (Table 
3). The NNT were relatively stable in all these analyses. However, there was no 
heterogeneity between trials when only the two trials that used “proportion with no 
straining during defecation” to define response to therapy (I2=0%, χ2 P=0.77), the two 
trials that used non-prebiotics (I2=0%, χ2 P=0.69), and when the three studies that 
used high dose (I2=0%, χ2 P=0.61) were included in the analysis. Sub-group 
analyses demonstrated no statistically significant differences in efficacy according to 
definition of response to therapy, type of fibre used, fibre solubility in water, and 
prebiotics versus non-prebiotics (interaction P > 0.10). In contrast, the subgroup 
analysis evaluating low (≤15g/d) versus high dose (>15g/d) suggested an increased 
effect with high dose (interaction P=0.09), partly explaining the heterogeneity 
observed across all studies. The optimal information size was calculated on the basis 
of a relative risk reduction of response to therapy of 30%. Optimal information size 
(617 individuals) was greater than the total sample size (287 participants), while the 
number of events across trials was relatively low (174 events) (Table 4). 
 
Stool frequency 
Continuous data on stool frequency were reported by six studies including 406 
patients.38-43 Overall, fibre supplementation significantly increased stool frequency 
compared with placebo (SMD=0.39; 95% CI 0.03 to 0.76; P=0.03), indicating a 
moderate effect size, albeit with statistically significant heterogeneity between studies 
  
 
13 
 
(I2=56%, χ2 P=0.04) (Figure S1). Results of subgroup analyses (Figure 2) showed 
no differences in efficacy according to type of fibre used (interaction P= 0.81), and 
prebiotics versus non-prebiotics (interaction P=0.91), although psyllium and non-
prebiotics increased stool frequency (P=0.0005). In addition, there was no 
heterogeneity between trials when only the two trials that used psyllium, and the two 
trials that used non-prebiotics were included in the analysis (I2=0%, χ2 P=0.87). 
Subgroup analyses suggested a possible increased effect with high dose (interaction 
P=0.17). High dose (>15g/d) fibre supplementation significantly increased stool 
frequency compared with placebo (SMD=0.77; 95% CI 0.03 to 1.51; P=0.04), 
indicating a large effect size. However, statistically significant heterogeneity between 
studies existed (I2=71%, χ2 P=0.06). Results of subgroup analysis according to 
sample size revealed a borderline statistically significant increase in stool frequency 
when studies that recruited less than 50 participants (P=0.003) were included in the 
analysis (interaction P=0.10). 
 
Stool consistency 
Stool consistency was reported as a continuous end point in five studies including 
346 patients.38-40, 42-43 Overall, fibre supplementation significantly softened stool 
consistency compared with placebo (SMD=0.35; 95% CI 0.04 to 0.65; P=0.02), 
indicating a moderate effect size, however heterogeneity between studies existed 
(I2=34%, χ2 P=0.19) (Figure S2). Heterogeneity between trials was lower when only 
the two trials that used psyllium and when only the two trials that used non-prebiotics 
were included in the analysis (I2=8%, χ2 P=0.30). Sub-group analyses showed no 
difference in efficacy according to type of fibre used (interaction P=0.18) (Figure 3). 
However, psyllium (P=0.009) and a mixture of inulin with resistant maltodextrin 
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(P=0.008) softened stool consistency. Results of the subgroup analysis comparing 
prebiotics versus non-prebiotics, showed borderline statistically significant 
improvement in stool consistency when studies that used non-prebiotics (P=0.009) or 
a mixture of a prebiotic/non-prebiotic (P=0.008) were included in the analysis 
(interaction P=0.10). The subgroup hypothesis evaluating single fibres versus 
mixtures of (multiple) fibre suggested an increased effect with mixtures of fibre 
(P=0.008) (interaction P=0.09). Furthermore, there were subgroup differences by 
dose of fibre used (interaction P=0.06) showing an increased effect on stool 
consistency with high dose (>15g/d) (P=0.006), partly explaining the heterogeneity 
observed across all studies. 
 
Gut microbiota concentrations 
The effect of fibre supplementation on fecal bifidobacteria and clostridia 
concentrations was reported in three studies. Bacterial counts were assessed via 
molecular techniques [two studies used the quantitative polymerase chain reaction40, 
41 and one study used fluorescence in situ hybridization43]. Bifidobacteria counts were 
reported in three studies, including 151 patients.40-41, 43 Overall, fibre supplementation 
did not significantly increase bifidobacteria numbers compared with placebo 
(SMD=0.43; 95% CI −0.20 to 1.07; P=0.18), and statistically significant heterogeneity 
between studies existed (I2=72%, χ2 P=0.03) (Figure S3). Sub-group analyses were 
performed to explore possible causes of the significant heterogeneity observed 
(Figure 4). The subgroup analysis comparing prebiotics versus non-prebiotics 
showed a statistically significant increase in bifidobacteria counts with prebiotics 
(SMD=0.75; 95% CI 0.33 to 1.18; P=0.0005) [inulin (P=0.02) and galacto-
oligosaccharides (GOS) (P=0.01)] (interaction P =0.008). In addition, there was no 
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heterogeneity between trials when only the two trials that used prebiotics were 
included in the analysis (I2=0%, χ2 P=0.78) (Figure S3). Two studies, including 101 
patients, reported data on clostridia counts.41, 43 Clostridia levels were significantly 
reduced with fibre supplementation compared to placebo (SMD=−0.66; 95% CI −1.29 
to −0.02; P=0.04), indicating a moderate effect size, although heterogeneity between 
studies existed (I2=56%, χ2 P=0.13). 
 
Adverse events 
None of the studies reported total number of adverse events or patient withdrawal 
because of fibre side effects. Nevertheless, three studies reported continuous data 
regarding individual gastrointestinal adverse events (flatulence and bloating). Three 
studies, including 115 patients, provided data on flatulence.40, 43-44 Overall, flatulence 
was significantly higher with fibre supplementation compared to placebo (SMD=0.56; 
95% CI 0.12 to 1.00; P=0.01), indicating a moderate effect size, with low 
heterogeneity between studies detected (I2=23%, χ2 P=0.27) (Figure S4). Bloating 
was reported in three studies, including 115 patients.40, 43-44 Fibre supplementation 
increased bloating compared with placebo (SMD=0.36; 95% CI −0.01 to 0.74; 
P=0.06) with borderline statistical significance. No heterogeneity between studies 
existed (I2=0%, χ2 P=0.94) (Figure S5). 
 
Publication bias 
The studies identified herein were too few in number to assess for evidence of 
asymmetry, and in turn for evidence of publication bias or other small study effects.36  
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Risk of bias 
None of the studies was at low risk of bias, both at the study (Figure S6) and 
outcome level (data available on request), and none of the trials followed an 
intention-to-treat analysis. Attrition bias (incomplete outcome data) and reporting bias 
(selective reporting) were prevalent, whereas performance bias (blinding of 
participants and personnel) and other bias were low amongst trials, both at the study 
(Figure S6) and outcome level (data available on request). GRADE criteria were 
applied to interpret results and assess overall quality of evidence (confidence in 
effect estimates) for each outcome (Table 4). The quality of evidence in terms of 
response to therapy, stool frequency, and adverse events was graded as low, 
whereas the confidence in the effect estimates for stool consistency and gut 
microbiota concentrations was graded as very low. 
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DISCUSSION 
This meta-analysis demonstrates that fibre supplementation is more effective than 
placebo for the treatment of CIC in adults. However, there is only low quality 
evidence that fibre is moderately effective. Furthermore, individual gastrointestinal 
side effects (e.g. flatulence) were higher in patients receiving fibre, although no 
patient withdrew because of fibre side effects. Only four trials38, 41-42, 44 adhered to the 
ROME committee’s recommendations45 by reporting global dichotomous data on 
response to therapy. The NNT with fibre to result in response to therapy was 
between 2 and 3, with subgroup analyses suggesting that high dose (>15g) was the 
most effective, with a NNT of 2. However, the definitions of response to therapy were 
inconsistent, and placebo rate of 44% was very high (e.g. in comparison to a placebo 
response of 27%, shown in a meta-analysis of laxatives in CIC).46 In addition, the 
optimal information size (617 individuals) was not met (287 participants), thus 
lowering confidence in estimates of effect for imprecision.30 Hence the effect size and 
NNT obtained from this meta-analysis need to be treated with caution.  
 
Prebiotics (inulin and GOS) seem to have no benefit over placebo in increasing stool 
frequency. The most robust evidence for an individual fibre seems to be for psyllium 
(a non-prebiotic). High fibre dose (>15g) was found to increase stool frequency with a 
large effect size. The most recent meta-analysis on the efficacy of laxatives in CIC 
demonstrated similar efficacy to the data for high fibre dose;46 both osmotic laxatives, 
including polyethylene glycol (~17g once or twice daily), and stimulant laxatives [e.g. 
bisacodyl (10 mg)] significantly increased stool frequency with a large effect size.46 
However, the fact that small sample-sized studies (<50 participants) showed higher 
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increases in stool frequency suggests the possibility of small study bias, given that 
smaller studies tend to show larger estimated effects than larger studies.47 
 
Fibre supplementation moderately softened stool consistency, also with a dose-
dependent effect. Psyllium showed greater effect on stool consistency compared to 
prebiotics (GOS and inulin). Psyllium (ispaghula husk), obtained from the seeds of 
plantago ovata, is a soluble viscous fibre with a high water-holding capacity that 
normalizes stool form.48 Stool water content has been highly associated with stool 
consistency, and a relatively small increase in stool water content has been shown to 
result in a relatively large stool softening effect.15,49 GOS and inulin are highly 
fermentable and are almost completely fermented in the colon, and despite high 
initial water-holding capacity, their fermentation results in a loss of water holding 
capacity and thus they have little effect on stool consistency.16 In contrast, psyllium is 
only partially fermented in the gut and the stool softening effect is a direct 
consequence of its ability to form a gel and hold many times its own weight in 
water.16 
 
In terms of side effects, flatulence and bloating were moderately increased after fibre 
consumption with a trend towards a dose-dependent effect. This might partly explain 
why patients (especially those with pre-existing symptoms of bloating) often poorly 
tolerate fibre supplementation.18 However, some degree of spontaneous unblinding 
was arguably present in these trials because of the effect of fibre on bowel 
symptoms, and it is likely to have affected subjective symptom assessments.50 
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Preliminary data have proposed a role for abnormal gut microbiota composition, so-
called dysbiosis, in the pathogenesis of CIC.51 Patients with CIC have been found to 
have lower concentrations of ‘beneficial’ bacteria (e.g. bifidobacteria) and higher 
concentrations of ‘pathogenic’ bacteria (e.g. clostridia).51 Pooled results with 
prebiotics (GOS and inulin) showed a statistically significant increase in bifidobacteria 
counts with a large effect size. Both GOS and inulin can be metabolized by 
bifidobacteria,52 though GOS is more bifidogenic,53 compatible with a higher effect 
size. In addition, fibre supplementation significantly lowered clostridia counts 
compared to placebo, with a moderate effect size. However, whether these beneficial 
quantitative changes in gut microbiota composition can lead to changes in 
gastrointestinal transit, which may benefit symptoms of constipation, is still unknown. 
Consequently, findings in relation to the microbiota-dependent or microbiota-
independent effect of fibre on gastrointestinal transit require confirmation in future 
studies. 
 
Strengths and limitations 
This systematic review and meta-analysis strictly adhered to recommended 
methodology, including a comprehensive search strategy, which included searching 
the ‘grey’ literature to minimize publication bias. Only RCTs were selected, and 
foreign language articles were translated to further minimize bias. Both the eligibility 
assessment and data extraction were performed independently and in duplicate. 
Authors of individual studies were also contacted in order to obtain supplementary 
information, where required. We used an intention-to-treat analysis and data were 
pooled with a random effects model to provide a more conservative estimate of the 
efficacy of fibre in CIC. We also conducted subgroup analyses to assess 
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heterogeneity in results. Finally, we used the GRADE approach, an internationally 
recognized method of rating evidence, to assess quality of evidence in addition to 
reporting risk of bias. Limitations of the present study derive from the quality and 
reporting of the included trials. None of the studies identified was at low risk of bias, 
both at the study and outcome level, sufficient in itself to negatively affect the 
interpretation of results.54 Furthermore, none of the trials followed an intention-to-
treat analysis potentially resulting in an over-estimation of efficacy of fibre 
supplementation.55 Application of GRADE criteria indicated results were of low 
quality, mainly due to study limitations, inconsistency and imprecision. Controversy 
remains over whether a meta-analysis should be performed due to concerns over the 
methodological quality of the studies identified, due to the considerable variability in 
the type of fibre studied, and due to the different habitual fibre intake level among the 
participants. The detection of heterogeneity in some of our analyses might reflect this 
variability. Different types of fibre have different physiological properties,50 and 
therefore, the therapeutic benefit may be fibre-specific. Unfortunately, the small 
number of studies available with each type of fibre in the subgroup analyses did not 
enable us to perform robust type-specific comparisons, and thus results should be 
interpreted with caution. Insoluble fibre has been also shown to alter colonic function 
through a stool bulking effect17 and through mechanical stimulation/irritation of the 
gut mucosa,56-57 but only one trial used insoluble fibre.44 
 
Comparison with other studies 
To the best of our knowledge, this is the first meta-analysis to assess available data 
on the efficacy of fibre supplementation in adults with CIC. Another recent meta-
analysis58 mainly focused on pediatric patients, with only one trial including adult 
  
 
21 
 
patients.44 This study also included patients with organic constipation rather than 
being conducted exclusively in patients with CIC. A systematic review performed 
exclusively in adult patients with CIC was published in 2011,22 and comprised six 
trials.38-39, 42, 44, 59-60 Of these, we excluded two studies59-60 (in which the effect of fibre 
supplementation could not be isolated), and identified three additional studies,40-41, 43 
two of which40-41 were published in the intervening four years, underlining the 
continuing interest in the manipulation of the gut microbiota through prebiotic 
supplementation as a potential therapy for CIC. Our meta-analysis demonstrated that 
prebiotic supplementation can beneficially alter gut microbiota concentrations. Within 
the most recent American College of Gastroenterology guidelines on the 
management of CIC in adults,11 a meta-analysis examining the effect of fibre on 
response to therapy identified only three trials,38, 42, 59 with pooled results suggesting 
a beneficial effect of fibre compared to placebo, with a NNT of 2, similar to that found 
in the current study. Finally, a systematic review without meta-analysis by Rao and 
colleagues was published in 2015,61 though the database search for this review was 
limited to a 10 year time period (2004-2014). Furthermore, studies with cross-over 
design and short washout periods (1–2 weeks) were considered eligible, thus 
increasing the carryover effect risk. Moreover, not all studies included were RCTs, 
and studies that used natural fibre (e.g. prunes), instead of a fibre supplement, were 
not excluded. Prunes also contain sorbitol, a polyol with osmotic laxative effect,62 
which might have skewed results. 
 
Implications for fibre supplementation recommendations 
Fibre supplements are food products and therefore are relatively safe, inexpensive 
and are widely available.63 Moreover, their use has been also associated with a 
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diminution in colorectal cancer risk compared to non-fibre laxative use.64 Therefore, 
they are a reasonable first-line therapy for CIC albeit with the caveat that up to 50% 
of patients will be dissatisfied with their effect.19 It remains unclear which type of fibre 
is the most efficacious, although the most robust evidence seems to be for psyllium 
(a soluble, non-prebiotic fibre). It also remains unclear whether one type of fibre will 
provide relief to all patients, or whether there may be particular subtypes of this 
heterogeneous condition that might respond preferentially.65 The aforementioned 
dissatisfaction with fibre is likely to be a consequence of increased gastrointestinal 
adverse events, such as flatulence and bloating,8 and warrants discussion with the 
patient prior to institution. 
 
Conclusion 
 
Current guidelines recommend the use of fibre supplementation as first-line 
treatment for CIC. However, overall there is only low quality evidence to support such 
a recommendation. Meta-analysis demonstrated that fibre supplementation is 
moderately effective with a dose-dependent effect but also causes moderate 
gastrointestinal side effects, again in a dose-dependent manner. Nevertheless, none 
of the studies included was at low risk of bias, sufficient in itself to negatively affect 
the interpretation of results. Hence, the paucity of high quality data highlights the 
need for further large, methodologically rigorous RCTs of fibre supplementation in 
CIC, adhering to the ROME Foundation criteria, before any recommendation 
regarding its risk-benefit profile can be definitively promoted.  
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TABLES 
 
Table 1. Definition of chronic idiopathic constipation used in randomised controlled trials of fibre supplementation in adults. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CIC=chronic idiopathic constipation; BM=bowel movements. 
 
 
 
 
 
 
Study Diagnostic criteria for CIC Details of diagnostic criteria  
 
 
Fenn, 198638 
 
 
Clinical diagnosis 
 
Patients suffering from functional 
 constipation 
 
Ashraf, 199539 
 
 
Clinical diagnosis 
 
Patients with chronic idiopathic 
constipation confirmed by prospectively 
administered stool diaries 
 
Marteau, 201140 
 
 
Rome III criteria 
 
Patients suffering from functional 
constipation according to the Rome definition 
 (<3 stools/week and/or straining in defecation) 
 
Waitzberg, 201241 
 
 
Self-reported 
 
Females with at least 3 months of  
primary constipation defined as less than 
3 bowel movements per week 
 
Lopez Roman, 200842 
 
 
Rome II criteria 
 
Patients meeting the Rome II criteria 
for chronic idiopathic constipation 
 
Surakka, 200943 
 
 
Self-reported 
 
Patients with difficulties in intestinal 
 function (including fewer than 5 BM per week 
or continuous difficulties in defecation or both)  
 
Badiali, 199544 
 
 
 
Clinical diagnosis 
 
Patients with prolonged large bowel transit 
 seeking medical advice for chronic primary constipation 
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Table 2. Characteristics of included randomised controlled trials of fibre supplementation in chronic idiopathic constipation in adults. 
GOS=galacto-oligosaccharides; NR=not reported (study did not report any dichotomous data on response to therapy); PHGG=partially hydrolyzed guar gum; RM=resistant 
maltodextrin. 
 
 
Study Country Setting Study 
design 
Criteria used 
to define 
response to 
therapy 
No. of 
patients 
(% female) 
Age  
Mean 
(range) 
(years)  
Fibre 
used 
Water 
solubility 
 
Prebiotics Daily 
Dose 
(g) 
 
Form Duration 
of 
therapy 
 
Fenn,  
198638 
 
 
UK 
 
Primary 
care 
 
Single blind, 
parallel 
group 
 
Proportion 
with an 
improvement 
in global 
symptoms 
 
201 
(75%) 
 
49 
(17-70) 
 
Psyllium 
 
Soluble 
 
Non 
prebiotic 
 
19.2 
 
Powder 
 
2 weeks 
 
Ashraf,  
199539 
 
 
USA 
 
Tertiary 
care 
 
Double blind, 
parallel 
group 
 
NR 
 
22 
(64%) 
 
51 
(40-75) 
 
Psyllium 
 
Soluble 
 
Non 
prebiotic 
 
10.2 
 
Powder 
 
8 weeks 
 
Marteau, 
201140 
 
 
France 
 
Primary 
care 
 
Double blind, 
parallel 
group 
 
NR 
 
50 
(88%) 
 
57 
(50-70) 
 
Inulin 
 
Soluble 
 
Prebiotic 
 
15 
 
Powder 
 
4 weeks 
 
Waitzberg, 
201241 
 
 
Brazil 
 
Primary 
care 
 
Double blind, 
parallel 
group 
 
Proportion 
with 
constipation 
relief 
 
60 
(100%) 
 
38 
(18-65) 
 
Inulin & 
PHGG 
 
Soluble 
 
Prebiotic & 
non 
prebiotic 
 
15 
 
Powder 
 
3 weeks 
 
Lopez 
Roman, 
200842 
 
 
Spain 
 
Tertiary 
care 
 
Double blind, 
parallel 
group 
 
Proportion 
with no 
straining 
during 
defecation 
 
32 
(88%) 
 
47 
(17-77) 
 
Inulin & 
RM 
 
Soluble 
 
Prebiotic & 
non 
prebiotic 
 
22.5 
 
 
Milk 
 
20 days 
  
Surakka, 
200943 
 
 
Finland 
 
Tertiary 
care 
 
Double blind, 
cross-over 
 
NR 
 
41 
(76%) 
 
68 
(60-80) 
 
GOS 
 
Soluble 
 
Prebiotic 
 
10 
 
Yoghurt 
 
3 weeks 
Badiali, 
199544 
 
 
Italy Tertiary 
care 
Double blind, 
cross-over 
Proportion 
with no 
straining 
during 
defecation 
24 
(92%) 
41 
(18-65) 
Wheat 
bran 
Insoluble Non 
prebiotic 
19.8 Powder 4 weeks 
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Table 3. Sub-group analyses of efficacy of fibre in resulting in response to therapy in adults with chronic idiopathic constipation. 
 
 Number of 
studies 
Number of 
patients 
RR of success to 
respond to therapy 
(95% CI) 
Sig. Interaction 
P value 
χ2 
P value 
I2 Number 
needed to treat 
(95% CI) 
All studies 438,41-42,44 287 1.71 (1.2 to 2.42) 0.003*  0.27 24% 3 (2.6 to 3.4) 
Definition of response to therapy     0.23    
Proportion with no straining 
during defecation 
242,44 44 2.70 (1.19 to 6.11) 0.02*  0.77 0% 2 (1.7 to 2.3) 
Other definition 238,41 243 1.46 (0.82 to 2.58) 0.20  0.10 64% N/A 
Type of fibre     0.90    
Psyllium 138 197 1.80 (1.45 to 2.25) <0.00001*  N/A N/A 3 (2.9 to 3.1) 
Wheat bran 144 16 2.33 (0.66 to 8.22) 0.19  N/A N/A N/A 
Mixture of inulin with PHGG or RM 241-42 74 1.59 (0.53 to 4.75) 0.41  0.08* 67% N/A 
Fibre solubility     0.61    
Soluble fibre 338,41-42 271 1.65 (1.03 to 2.62) 0.04*  0.16 46% 3 (2.5 to 3.5) 
Insoluble fibre 144 16 2.33 (0.66 to 8.22) 0.19  N/A N/A N/A 
Prebiotics vs. non-prebiotics     0.81    
Mixture of a prebiotic/non-
prebiotic 
241-42 74 1.59 (0.53 to 4.75) 0.41  0.08* 67% N/A 
 Non-prebiotics 238,44 213 1.82 (1.46 to 2.26) <0.00001*  0.69 0% 2 (1.9 to 2.1) 
Dose of treatment     0.09*    
Low dose (≤15g) 141 46 0.98 (0.49 to 1.96) 0.96  N/A N/A N/A 
High dose (>15g) 338,42,44 241 1.85 (1.50 to 2.29) <0.00001*  0.61 0% 2 (1.8 to 2.2) 
*=statistically significant; CI=confidence interval; Interaction P value=P value of tests for interactions; N/A=not applicable (too few studies to assess 
heterogeneity and/or relative risk not statistically significant to calculate number needed to treat); PHGG=partially hydrolyzed guar gum; RM=resistant 
maltodextrin; RR=relative risk; Sig.=significance. 
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Table 4. GRADE system approach for quality of evidence assessment of each outcome. 
 
 
 
Outcome 
 
 
No. of 
studies 
 
 
No. of 
patients 
Quality assessment 
 
 
 
Quality of 
evidence 
Study 
limitations 
Inconsistency Indirectness Imprecision Publication 
bias 
 
Response to 
therapy 
 
438,41-42,44 
 
287 
 
Serious 
limitations* 
 
 
 
 
 
OIS greater than number of 
patients; relatively low number 
of events 
 
 
Not  
evaluable 
 
, 
Low 
 
 
Stool frequency 
 
638-43 
 
406 
 
Serious 
limitations*  
 
Significant heterogeneity 
between studies; variability in 
results 
 
 
 
 
Modest number of patients 
studied with wide 95% CIs 
 
 
 
 
, 
Low 
 
 
Stool consistency 
 
538-40,42-43 
 
346 
 
Serious 
limitations* 
  
 
Moderate heterogeneity 
between studies 
 
 
 
 
Very modest number of patients 
studied with wide 95% CIs 
 
 
Not  
evaluable 
 
, 
Very low 
 
 
Gut microbiota 
concentrations 
 
340-41,43 
 
151 
 
Serious 
limitations* 
 
 
 
Significant heterogeneity 
between studies; variability in 
results 
 
 
 
 
Only a small number of patients 
studied with wide 95% CIs 
 
 
Not  
evaluable 
 
, 
Very low 
 
 
Adverse events 
 
340,43-44 
 
115 
 
Serious 
limitations* 
 
 
 
 
 
 
Only a small number of patients 
studied with wide 95% CIs  
 
Not  
evaluable 
 
, 
Low 
 
*=all trials were at high risk of bias and all failed to adhere to an intention-to-treat analysis, there was also high attrition (incomplete outcome data) and reporting bias 
(selective reporting) amongst trials;  The criterion was fulfilled;  The criterion was not fulfilled; CI=confidence interval; OIS=optimal information size. 
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FIGURES 
Figure 1 PRISMA flow diagram of studies in systematic review. 
 
Figure 2 Forest plot of randomised controlled trials in adults with chronic idiopathic 
constipation comparing fibre with placebo/control. Standardized mean differences 
(95% CIs) for stool frequency among subgroups with the use of a random-effects 
model. GOS=galacto-oligosaccharides; PHGG=partially hydrolyzed guar gum; 
RM=resistant maltodextrin. 
 
Figure 3 Forest plot of randomised controlled trials in adults with chronic idiopathic 
constipation comparing fibre with placebo/control. Standardized mean differences 
(95% CIs) for stool consistency among subgroups with the use of a random-effects 
model. GOS=galacto-oligosaccharides; RM=resistant maltodextrin. 
 
Figure 4 Forest plot of randomised controlled trials in adults with chronic idiopathic 
constipation comparing fibre with placebo/control. Standardized mean differences 
(95% CIs) for fecal bifidobacteria concentrations among subgroups with the use of a 
random-effects model. GOS=galacto-oligosaccharides; PHGG=partially hydrolyzed 
guar gum.  
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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SUPPORTING INFORMATION 
 
 
Table S1 Detailed Search Strategy – Medline. 
Constipation/ OR constipation.mp. OR defecation disorders.mp. OR evacuation disorders.mp. OR 
gastrointestinal transit/ OR gastrointestinal transit.mp. OR slow transit.mp.  
 
AND 
Adult/ 
AND 
Fibre.mp. OR Fiber.mp. OR non starch polysaccharides.mp. OR prebiotic*.mp. OR 
oligosaccharides.mp. OR oligofructose.mp. OR fructans.mp. OR plant extracts.mp. OR inulin.mp. 
OR Resistant maltodextrin.mp. OR cellulose.mp. OR pectin.mp. OR ß-glucan.mp. OR soluble corn 
fibre.mp. OR soluble corn fiber.mp. OR pullulan.mp. OR glucomannan.mp. OR galactomannan.mp. 
OR arabinans.mp. OR arabinogalactans.mp. OR arabinoxylans.mp. OR polydextrose.mp. OR 
bran.mp. OR acacia gum.mp. OR guar gum.mp. OR psyllium/ OR psyllium.mp. OR ispaghula 
husk.mp. OR plantago ovata.mp. OR fybogel.mp. OR exp dietary fiber/ OR exp starch/ 
 
AND 
Randomized controlled trial.pt. OR controlled clinical trial.pt. OR randomized.ab. OR placebo.ab. 
OR clinical trials as topic.sh. OR randomly.ab. OR trial.ti. 
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Figure S1 Forest plot of randomised controlled trials in adults with chronic idiopathic 
constipation comparing fibre with placebo/control. Standardized mean differences 
(95% CIs) for stool frequency with the use of a random-effects model. IV=inverse 
variance. 
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Figure S2 Forest plot of randomised controlled trials in adults with chronic idiopathic 
constipation comparing fibre with placebo/control. Standardized mean differences 
(95% CIs) for stool consistency with the use of a random-effects model. IV=inverse 
variance. 
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Figure S3 Forest plot of randomised controlled trials in adults with chronic idiopathic 
constipation comparing fibre with placebo/control. Standardized mean differences 
(95% CIs) for fecal bifidobacteria concentrations (prebiotics versus non-prebiotics) 
with the use of a random-effects model. IV=inverse variance. 
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Figure S4 Forest plot of randomised controlled trials in adults with chronic idiopathic 
constipation comparing fibre with placebo/control. Standardized mean differences 
(95% CIs) for flatulence (low dose versus high dose) with the use of a random-effects 
model. IV=inverse variance. 
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Figure S5 Forest plot of randomised controlled trials in adults with chronic idiopathic 
constipation comparing fibre with placebo/control. Standardized mean differences 
(95% CIs) for bloating (low dose versus high dose) with the use of a random-effects 
model. IV=inverse variance. 
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Figure S6 Overall risk of bias summary and risk of bias graph for all studies and 
outcomes together (study level). 
 
 
 
 
 
 
 
 
 
